Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Solriamfetol hydrochloride by Axsome Therapeutics for Binge Eating Disorder: Likelihood of Approval
Solriamfetol hydrochloride is under clinical development by Axsome Therapeutics and currently in Phase III for Binge Eating Disorder. According to...
Solriamfetol hydrochloride by Axsome Therapeutics for Major Depressive Disorder: Likelihood of Approval
Solriamfetol hydrochloride is under clinical development by Axsome Therapeutics and currently in Phase III for Major Depressive Disorder. According to...
Solriamfetol hydrochloride by Axsome Therapeutics for Fatigue: Likelihood of Approval
Solriamfetol hydrochloride is under clinical development by Axsome Therapeutics and currently in Phase II for Fatigue. According to GlobalData, Phase...
Solriamfetol hydrochloride by Axsome Therapeutics for Attention Deficit Hyperactivity Disorder (ADHD): Likelihood of Approval
Solriamfetol hydrochloride is under clinical development by Axsome Therapeutics and currently in Phase III for Attention Deficit Hyperactivity Disorder (ADHD)....
Reboxetine by Axsome Therapeutics for Type 1 Narcolepsy (Narcolepsy with Cataplexy): Likelihood of Approval
Reboxetine is under clinical development by Axsome Therapeutics and currently in Phase III for Type 1 Narcolepsy (Narcolepsy with Cataplexy)....
Risk adjusted net present value: What is the current valuation of Axsome Therapeutics's Reboxetine?
Reboxetine is a small molecule commercialized by Axsome Therapeutics, with a leading Phase III program in Type 1 Narcolepsy (Narcolepsy...